Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis
Go back to Pfizer Announces Positive Top-Line Results from the First Phase 3 Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis| Pfizer Inc. (NYSE: PFE) | Delayed: 30.15 +0.20 (0.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.95 | 52 Week High | $37.39 | |||
| Open | $30.51 | 52 Week Low | $28.25 | |||
| Day High | $30.65 | P/E | 18.27 | |||
| Day Low | $30.14 | EPS | $1.65 | |||
| Volume | 7,234,302 | |||||



